Biocon launches its Glucagon-like Peptide-1, Liraglutide, in the Netherlands

Lupin launches Glucagon for Injection USP, 1mg/Vial in US

Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus

Lupin receives USFDA approvals for Liraglutide and Glucagon injectable products

Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India

Biocon partners with Tabuk to commercialize its Glucagon-like peptide-1 products in the Middle East

Gan & Lee gets U.S. FDA clearance for novel glucagon-like peptide-1 analogue

The investigational compound, GZR18, is a novel analogue of glucagon-like peptide-1 (GLP-1), an incretin hormone responsible for many glucoregulatory effects

Q2 2026 drug catalysts put Replimune, Arvinas and Boehringer in sharp focus: GlobalData

Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning

New diabetes drug UBT251 shows strong phase 2 results in China

Eli Lilly’s experimental drug Retatrutide shows major breakthrough in Type 2 diabetes trial

Lilly expands access to Zepbound weight-loss drug with $299 monthly self-pay option

The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect

Novo Nordisk’s "Triple G" drug UBT251 triggers nearly 20% weight loss in 24 weeks

UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies